179 related articles for article (PubMed ID: 37833461)
1. DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune responses through cGAS-STING pathway.
Fan H; Liu W; Zeng Y; Zhou Y; Gao M; Yang L; Liu H; Shi Y; Li L; Ma J; Ruan J; Cao R; Jin X; Chen J; Cheng G; Yang H
Commun Biol; 2023 Oct; 6(1):1041. PubMed ID: 37833461
[TBL] [Abstract][Full Text] [Related]
2. Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways.
Dai M; Boudreault J; Wang N; Poulet S; Daliah G; Yan G; Moamer A; Burgos SA; Sabri S; Ali S; Lebrun JJ
Cancer Res; 2021 Mar; 81(5):1332-1346. PubMed ID: 33372040
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor of activated T cells c1 mediates p21-activated kinase 1 activation in the modulation of chemokine-induced human aortic smooth muscle cell F-actin stress fiber formation, migration, and proliferation and injury-induced vascular wall remodeling.
Kundumani-Sridharan V; Singh NK; Kumar S; Gadepalli R; Rao GN
J Biol Chem; 2013 Jul; 288(30):22150-62. PubMed ID: 23737530
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation.
Bockstaele L; Bisteau X; Paternot S; Roger PP
Mol Cell Biol; 2009 Aug; 29(15):4188-200. PubMed ID: 19487459
[TBL] [Abstract][Full Text] [Related]
5. The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer.
Liu C; Huang Y; Cui Y; Zhou J; Qin X; Zhang L; Li X; Li Y; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Hu D; Xiao R; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Qin T; You L; Lu F; Sun C
Front Immunol; 2021; 12():799171. PubMed ID: 35095879
[TBL] [Abstract][Full Text] [Related]
6. Targeting CDK4 and CDK6: From Discovery to Therapy.
Sherr CJ; Beach D; Shapiro GI
Cancer Discov; 2016 Apr; 6(4):353-67. PubMed ID: 26658964
[TBL] [Abstract][Full Text] [Related]
7. Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.
Jia Y; Domenico J; Swasey C; Wang M; Gelfand EW; Lucas JJ
PLoS One; 2014; 9(5):e97448. PubMed ID: 24848372
[TBL] [Abstract][Full Text] [Related]
8. Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer.
Sobhani N; Fassl A; Mondani G; Generali D; Otto T
Cells; 2021 Feb; 10(2):. PubMed ID: 33535617
[TBL] [Abstract][Full Text] [Related]
9. Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.
Rodríguez-Díez E; Quereda V; Bellutti F; Prchal-Murphy M; Partida D; Eguren M; Kollmann K; Gómez de Cedrón M; Dubus P; Cañamero M; Martínez D; Sexl V; Malumbres M
Blood; 2014 Oct; 124(15):2380-90. PubMed ID: 25157181
[TBL] [Abstract][Full Text] [Related]
10. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
Bortolozzi R; Mattiuzzo E; Trentin L; Accordi B; Basso G; Viola G
Biochem Pharmacol; 2018 Jul; 153():230-241. PubMed ID: 29408328
[TBL] [Abstract][Full Text] [Related]
11. Kaempferol suppresses proliferation and induces apoptosis and DNA damage in human gallbladder cancer cells through the CDK4/CDK6/cyclin D1 pathway.
Liu ZQ; Yao GL; Zhai JM; Hu DW; Fan YG
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1311-1321. PubMed ID: 33629301
[TBL] [Abstract][Full Text] [Related]
12. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Li Z; Razavi P; Li Q; Toy W; Liu B; Ping C; Hsieh W; Sanchez-Vega F; Brown DN; Da Cruz Paula AF; Morris L; Selenica P; Eichenberger E; Shen R; Schultz N; Rosen N; Scaltriti M; Brogi E; Baselga J; Reis-Filho JS; Chandarlapaty S
Cancer Cell; 2018 Dec; 34(6):893-905.e8. PubMed ID: 30537512
[TBL] [Abstract][Full Text] [Related]
13. Beyond DNA sensing: expanding the role of cGAS/STING in immunity and diseases.
Seok JK; Kim M; Kang HC; Cho YY; Lee HS; Lee JY
Arch Pharm Res; 2023 Jun; 46(6):500-534. PubMed ID: 37354378
[TBL] [Abstract][Full Text] [Related]
14. Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells.
Liu Y; Zhao Y; Han C; Ren C
Comput Math Methods Med; 2022; 2022():2402567. PubMed ID: 35535229
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer.
Storozynsky Q; Hitt MM
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238631
[TBL] [Abstract][Full Text] [Related]
16. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.
Wang H; Nicolay BN; Chick JM; Gao X; Geng Y; Ren H; Gao H; Yang G; Williams JA; Suski JM; Keibler MA; Sicinska E; Gerdemann U; Haining WN; Roberts TM; Polyak K; Gygi SP; Dyson NJ; Sicinski P
Nature; 2017 Jun; 546(7658):426-430. PubMed ID: 28607489
[TBL] [Abstract][Full Text] [Related]
17. CDK4 and CDK6 kinases: From basic science to cancer therapy.
Fassl A; Geng Y; Sicinski P
Science; 2022 Jan; 375(6577):eabc1495. PubMed ID: 35025636
[TBL] [Abstract][Full Text] [Related]
18. MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.
Bustos MA; Ono S; Marzese DM; Oyama T; Iida Y; Cheung G; Nelson N; Hsu SC; Yu Q; Hoon DSB
J Invest Dermatol; 2017 Sep; 137(9):1955-1964. PubMed ID: 28526299
[TBL] [Abstract][Full Text] [Related]
19. Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases.
Joshi I; Minter LM; Telfer J; Demarest RM; Capobianco AJ; Aster JC; Sicinski P; Fauq A; Golde TE; Osborne BA
Blood; 2009 Feb; 113(8):1689-98. PubMed ID: 19001083
[TBL] [Abstract][Full Text] [Related]
20. Inducible deletion of CDK4 and CDK6 - deciphering CDK4/6 inhibitor effects in the hematopoietic system.
Maurer B; Brandstoetter T; Kollmann S; Sexl V; Prchal-Murphy M
Haematologica; 2021 Oct; 106(10):2624-2632. PubMed ID: 32855282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]